medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2018, Number 1

<< Back Next >>

Rev Esp Med Quir 2018; 23 (1)

Neuroendocrine differentiation in invasive ductal breast carcinoma

Castelán-Maldonado EE, Peña-Ruelas CI, Sánchez-Garza JA, de La Rosa-Vélez EE

Language: Spanish
References: 18
Page: 20-25
PDF size: 233.99 Kb.


ABSTRACT

Background: Breast cancer is a heterogeneous disease with multiple histological subtypes, metastatic potential and variable prognosis. In 2003 the WHO recognized neuroendocrine carcinoma as a specific subtype of breast carcinoma in which the characteristic finding is the expression of chromogranin and/or synaptophysin. Methods: 70 cases of invasive ductal carcinoma were reviewed and classified according to the molecular subtype. Tissue array and immunohistochemistry was performed for chromogranin A, synaptophysin, GCDFP-15 and GATA3. The clinicopathological variables were obtained from the pathology report and clinical history. Results: Twenty-fourth (24/70, 34.3%) cases were positive for chromogranin and/or synaptophysin, the primary origin in the mammary tissue was corroborated by GATA3 and/or GCDFP-15. According to histological grade, 62.5% (15/24) were moderately differentiated. The predominant molecular subtype, with 29.2% (7/24), was triple negative. The overall 5-year survival rate were 50% in neuroendocrine differentiation and 46% in patients without differentiation (p = 0.675). Conclusions: Clinicopathological characteristics and overall survival are not significantly different in invasive ductal carcinoma with neuroendocrine differentiation.


REFERENCES

  1. Lakhani SR, Reis-Filho JS, van de Vijver MJ. Molecular pathology overview. En: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, editores. WHO classification of tumours of the breast. Lyon, France: IARC Press; 2012. p. 28.

  2. Maluf HM, Koerner FC. Carcinomas of the breast with endocrine differentiation: a review. Virchows Arch. 1994;425(5):449-57.

  3. Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, Eusebi V, et al. Invasive breast carcinoma. En: Tavassoli FA, Devilee P, editores. WHO classification of tumours of the breast. Lyon, France: IARC Press; 2003. p. 32.

  4. Bussolati G, Badve S. Carcinomas with neuroendocrine features. En: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, editores. WHO classification of tumours of the breast. Lyon, France: IARC Press; 2012. p. 62-3.

  5. Wachter DL, Hartmann A, Beckmann MW, Fasching PA, Hein A, Bayer CM, et al. Expression of neuroendocrine markers in different molecular subtypes of breast carcinoma. Biomed Res Int. 2014;2014(408459):9.

  6. Angarita FA, Rodríguez JL, Meek E, Sánchez JO, Tawil M, Torregrosa L. Locally-advanced primary neuroendocrine carcinoma of the breast: Case report and review of the literature. World J Surg Oncol. 2013;11:128.

  7. Mohanty SK, Kim SA, DeLair DF, Bose S, Laury AR, Chopra S, et al. Comparison of metastatic neuroendocrine neoplasms to the breast and primary invasive mammary carcinomas with neuroendocrine differentiation. Mod Pathol. 2016;29(8):788-98.

  8. Righi L, Sapino A, Marchiò C, Papotti M, Bussolati G. Neuroendocrine differentiation in breast cancer: Established facts and unresolved problems. Semin Diagn Pathol. 2010;27(1):69-76.

  9. Tajima S, Horiuchi H. Neuroendocrine tumor, well differentiated, of the breast: a relatively high-grade case in the histological subtype. Case Rep Pathol. 2013;2013(204065):3.

  10. Wei B, Ding T, Xing Y, Wei W, Tian Z, Tang F, et al. Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. Cancer. 2010;116(19):4463-73.

  11. Ghanem S, Kabaj H, Naciri S, Glaoui M, Ismaili N, Benjaafar N, et al. Primary neuroendocrine carcinoma of the breast: a rare and distinct entity. J Cancer Res Exp Oncol. 2011;3(5):50-4.

  12. Sawaki M, Yokoi K, Nagasaka T, Watanabe R, Kagawa C, Takada H, et al. Prognostic importance of neuroendocrine differentiation in Japanese breast cancer patients. Surg Today. 2010;40(9):831-5.

  13. Fitzgibbons PL, Dillon DA, Alsabeh R, Berman MA, Hayes DF, Hicks DG, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. Arch Pathol Lab Med. 2014;138:595-601.

  14. Yang X, Cao Y, Chen C, Liu L, Wang C, Liu S. Primary neuroendocrine breast carcinomas: a retrospective analysis and review of literature. Onco Targets Ther. 2017;10:397-407.

  15. Wang J, Wei B, Albarracin CT, Hu J, Abraham SC, Wu Y. Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer. 2014;14:147.

  16. Kwon SY, Bae YK, Gu MJ, Choi JE, Kang SH, Lee SJ, et al. Neuroendocrine differentiation correlates with hormone receptor expression and decreased survival in patients with invasive breast carcinoma. Histopathology. 2014;64(5):647-59.

  17. Liu Y-H, Tsang JYS, Ni Y-B, Hlaing T, Chan S-K, Chan K-F, et al. Doublecortin- like kinase 1 expression associates with breast cancer with neuroendocrine differentiation. Oncotarget. 2016;7(2):1464-76.

  18. Calderón-Garcidueñas AL, Martínez-Reyes G, Gallardo-Gómez AI, Rojas- Martínez A, Cerda-Flores RM. Triple marker immunohistochemestry analysis in breast cancer mexican patients. Patologia (Mex). 2012;50(2): 72-9.




2020     |     www.medigraphic.com